MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSalud

4.23 8.46

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.89

Máximo

4.28

Métricas clave
By Trading Economics
Ingresos	-11M -46M
Ventas	-815K 4.2M
Margen de beneficio	-1,077.237
Empleados	596
EBITDA	16M -40M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+59.38% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 ago 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	588M 1.2B
Apertura anterior	-4.23
Cierre anterior	4.23

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

118 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.99 / 2.635 Soporte y Resistencia

AbCellera Biologics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 jul 2025, 15:46 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250 Million Private Placement

9 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 jul 2025, 22:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 20:26 UTC

Ganancias

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 jul 2025, 19:18 UTC

Charlas de Mercado

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 jul 2025, 19:03 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 jul 2025, 18:31 UTC

Charlas de Mercado

Some Fed Officials Supported Considering July Cut -- Market Talk

9 jul 2025, 17:07 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk -2-

9 jul 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

9 jul 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

9 jul 2025, 16:14 UTC

Charlas de Mercado

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 jul 2025, 16:14 UTC

Adquisiciones, fusiones, absorciones

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 jul 2025, 16:12 UTC

Charlas de Mercado

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 jul 2025, 16:08 UTC

Charlas de Mercado

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 jul 2025, 15:31 UTC

Principales Movimientos del Mercado

BitMine Shares Fall After Closing of $250M Private Placement

9 jul 2025, 15:31 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 jul 2025, 15:27 UTC

Charlas de Mercado

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 jul 2025, 14:36 UTC

Adquisiciones, fusiones, absorciones

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 jul 2025, 14:31 UTC

Adquisiciones, fusiones, absorciones

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 jul 2025, 14:26 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

9 jul 2025, 14:26 UTC

Charlas de Mercado

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc Esperado

Precio Objetivo

By TipRanks

59.38% repunte

Estimación a 12 meses

Media 6.2 USD 59.38%

Máximo 10 USD

Mínimo 3 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.99 / 2.635Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

118 / 376 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.